Scientists at US University of Colorado’s Skaggs School of Pharmacy and Pharmaceutical Sciences have developed a novel test that helps monitor the efficacy of Truvada (tenofovir/ emtricitabine), a therapy received once daily for the prevention of HIV infection. The test uses a dried blood spot to assess the amount of tenofovir-diphosphate, a metabolite of tenofovir, in red blood cells. As a result of a long half-life, high amounts of tenofovir- diphosphate in the dried blood spot correspond with consistent dosing of Truvada, whereas low amounts correspond with inconsistent dosing.
Hey, check out all the engineering jobs. Post your resume today!